# Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

> **NCT00781846** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 17 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** ridaforolimus
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00781846
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781846, "Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00781846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*